Marksans Pharma is not your regular “chemists ki dukaan” listed on NSE. It’s the OTC king supplying pills, syrups, and gels to Walmart, Walgreens, Tesco, Boots, Woolworths, and Coles. 74% of revenue comes from OTC, meaning Marksans is the “Dolo-650” for western supermarkets. With ₹2,652 Cr sales, ₹350 Cr profit, and P/E of 22, the company looks like a value pick—until you see the last 12 months return: -36%. Basically, the market thinks it’s selling Hajmola in a Viagra wrapper.
2. Introduction
Pharma companies usually scream about “complex injectables” or “biologics.” Marksans, on the other hand, is happily selling cough syrup in Tesco and ibuprofen to Walmart. Think of it as the Reliance Fresh of generics: volume, shelf space, brand labels.
The pitch is simple:
Why burn cash in India when you can sell painkillers in the US and UK supermarkets with their massive retail chains?
Why struggle with pricing control under NPPA when you can be Boots’ favorite supplier of cold syrup?
Why stick to one segment when you can have 1,500 SKUs, from vitamins to anti-hair fall pills?
But here’s the catch: smallcap pharma is always one USFDA inspection away from disaster. Marksans had 5 observations in Goa (Apr 2024), but survived. Still, the stock is trading closer to its 52-week low than its high.
Question: Would you bet on a company whose biggest moat is—“we know Walmart’s buyer’s WhatsApp number”?
3. Business Model – WTF Do They Even Do?
Marksans works like a pharmaceutical wholesaler disguised as a manufacturer.
OTC (74% of revenue): Pain management (39% share), cough & cold (13%), vitamins (3.6%), anti-allergic (6%). Basically, the drug cabinet of every Indian mom repackaged for foreign retail shelves.
Prescription (26%): Cardiovascular, CNS, anti-diabetic, and anticancer—smaller slice, but gives them legitimacy.
Global presence:
USA (47%): Through Time Cap Labs, sells 50+ products to Target, Walmart, Walgreens, Kroger. The dream client list for any pharma vendor.
UK/Europe (40%): Through Bells Healthcare & Relonchem. Top 5 Indian pharma in UK OTC space. Supplies to Tesco, Boots, Asda, Morrisons.
Australia/NZ (9%): Nova Pharma supplies Woolworths, Aldi, Coles.
Rest of World (4%): Small presence in MENA & CIS.
Their pitch = global FMCG of pills. Your medicine shelf, their SKU.
4. Financials Overview
Metric
Latest Qtr (Jun’25)
YoY Qtr (Jun’24)
Prev Qtr (Mar’25)
YoY %
QoQ %
Revenue
620
591
708
+5.0%
-12.4%
EBITDA
100
128
127
-21.9%
-21.3%
PAT
58
89
91
-34.3%
-36.2%
EPS (₹)
1.3
2.0
2.0
-34.3%
-36.2%
Commentary: Quarterly profit fell like Sensex after Budget Day. Annualised EPS = ₹7.7, P/E ~22. Reasonable. But falling margins are flashing red.
EV/EBITDA Method: EV ₹7,272 Cr, EBITDA ~₹560 Cr. EV/EBITDA = 13x. Fair range 10–15x → ₹150 – ₹200/share.
DCF (growth 10%, WACC 12%): ₹130 – ₹180.
Fair Value Range: ₹130 – ₹200. CMP ₹169 sits neatly in range. Neither screaming bargain, nor bubble.
Disclaimer: Educational only, not investment advice.
6. What’s Cooking – News, Triggers, Drama
USFDA approvals (2024–25): Omeprazole, Loratadine, Gabapentin oral solution, Metformin. Basically, every medicine in your college hostel first aid box.
